Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US8816242098

SecurityTEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
InstitutionPitcairn Co
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Pitcairn Co closes position in TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)

On February 12, 2026 - Pitcairn Co filed a 13F-HR form disclosing ownership of 0 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) (US:TEVA) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 12, 2025 disclosing 51,651 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock). The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 0 -100.00 0
2025-11-12 2025-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 51,651 -12,598 -19.61 1,043 -3.07 0.0824
2025-08-19 2025-06-30 13F/A-1 TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 64,249 2,266 3.66 1,077 13.03 0.0705
2025-08-14 2025-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 15,708 -46,275 46 0.0027
2025-05-09 2025-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 61,983 1,096 1.80 953 -29.01 0.0574
2025-02-12 2024-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 60,887 8,312 15.81 1,342 41.61 0.0793
2024-11-12 2024-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 52,575 52,575 947 0.0560
2017-02-06 2016-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 0 -13,790 -100.00 0 -100.00
2016-11-09 2016-09-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 13,790 13,790 0.00 635 0.0790
2016-07-25 2016-06-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 0 -12,313 -100.00 0 -100.00
2016-04-29 2016-03-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 12,313 -458 -3.59 659 -21.45 0.0832
2016-02-10 2015-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 12,771 12,771 839 0.0932
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.